Related Experiment Video
Updated: Mar 22, 2026

Chromosome Preparation From Cultured Cells
Published on: January 28, 2014
Cell biology and genetics of minimal change disease
Moin A Saleem1, Yasuko Kobayashi2
1Paediatric Renal Medicine, University of Bristol, Bristol, UK; Children's Renal Unit, Bristol Royal Hospital for Children, Bristol, UK.
Abstract:
Minimal change disease (MCD) is an important cause of nephrotic syndrome and is characterized by massive proteinuria and hypoalbuminemia, resulting in edema and hypercholesterolemia. The podocyte plays a key role in filtration and its disruption results in a dramatic loss of function leading to proteinuria. Immunologic disturbance has been suggested in the pathogenesis of MCD. Because of its clinical features, such as recurrent relapse/remission course, steroid response in most patients, and rare familial cases, a genetic defect has been thought to be less likely in MCD. Recent progress in whole-exome sequencing reveals pathogenic mutations in familial cases in steroid-sensitive nephrotic syndrome (SSNS) and sheds light on possible mechanisms and key molecules in podocytes in MCD. On the other hand, in the majority of cases, the existence of circulating permeability factors has been implicated along with T lymphocyte dysfunction. Observations of benefit with rituximab added B cell involvement to the disease. Animal models are unsatisfactory, and the humanized mouse may be a good model that well reflects MCD pathophysiology to investigate suggested "T cell dysfunction" directly related to podocytes in vivo. Several candidate circulating factors and their effects on podocytes have been proposed but are still not sufficient to explain whole mechanisms and clinical features in MCD. Another circulating factor disease is focal segmental glomerulosclerosis (FSGS), and it is not clear if this is a distinct entity, or on the same spectrum, implicating the same circulating factor(s). These patients are mostly steroid resistant and often have a rapid relapse after transplantation. In clinical practice, predicting relapse or disease activity and response to steroids is important and is an area where novel biomarkers can be developed based on our growing knowledge of podocyte signaling pathways. In this review, we discuss recent findings in genetics and podocyte biology in MCD.
Insights
Minimal change disease (MCD) involves podocyte damage causing nephrotic syndrome. Recent research explores genetic factors and circulating factors, offering insights into disease mechanisms and potential biomarkers for treatment.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Minimal change disease (MCD) is a primary cause of nephrotic syndrome, characterized by massive proteinuria and podocyte injury.
- The pathogenesis of MCD is complex, with proposed roles for immunologic disturbances, including T and B lymphocyte dysfunction.
- While genetic defects were initially considered less likely, recent advances have identified mutations in familial cases of steroid-sensitive nephrotic syndrome (SSNS).
Purpose of the Study:
- To review recent findings in the genetics and podocyte biology of Minimal Change Disease (MCD).
- To discuss the proposed mechanisms, including circulating factors and immune system involvement, in MCD pathogenesis.
- To highlight the need for novel biomarkers for predicting disease activity and treatment response in MCD.
Main Methods:
- Review of recent literature on genetics, podocyte biology, and immunology in Minimal Change Disease (MCD).
- Analysis of findings from whole-exome sequencing in familial SSNS cases.
- Discussion of proposed animal models and circulating factors implicated in MCD.
Main Results:
- Pathogenic mutations have been identified in familial SSNS, providing insights into podocyte function.
- Circulating permeability factors and T lymphocyte dysfunction are implicated in the majority of MCD cases.
- Rituximab's efficacy suggests B cell involvement, further complicating the understanding of MCD pathogenesis.
Conclusions:
- Understanding the interplay between genetic factors, podocyte biology, and immune dysregulation is crucial for elucidating MCD mechanisms.
- Further research into circulating factors and podocyte signaling pathways is needed to develop effective biomarkers.
- Distinguishing MCD from other glomerular diseases like FSGS and predicting treatment responses remain clinical challenges.
More Related Videos
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Mutations
Animal Mitochondrial Genetics